EBVALLO (tabelecleucel)
EBVALLO is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant …
Ebvallo - European Medicines Agency (EMA)
Oct 14, 2022 · Ebvallo is a medicine used to treat adults and children from 2 years of age who, after receiving an organ- or a bone marrow-transplantation, develop a blood cancer called …
Tabelecleucel - Wikipedia
Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). [2][3] …
About EBVALLO: Mechanism of Action, Manufacturing, Treatment …
EBVALLO is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant …
Ebvallo (tabelecleucel): What is it and is it FDA approved? - Drugs.com
Jan 17, 2025 · Tabelecleucel (tab-cel) is an allogeneic, EBV-specific T-cell immunotherapy in development for the treatment of patients two years of age and older with Epstein-Barr virus …
Ebvallo (tabelecleucel) is an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy which targets and eliminates EBV-positive cells in a human leukocyte antigen (HLA)-restricted …
What is Ebvallo and what is it used for? Ebvallo is a medicine used to treat adults and children from 2 years of age who, after receiving an organ- or a bone marrow-transplantation, develop …
Efficacy | EBVALLO
EBVALLO is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant …
Atara Biotherapeutics Provides Regulatory and Business Update on ...
Jan 16, 2025 · EBVALLO, which was granted marketing authorization by the European Commission in December of 2022, is an allogeneic, EBV-specific T-cell immunotherapy …
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European ...
Dec 19, 2022 · EBV+ PTLD is a rare, acute, and potentially deadly hematologic malignancy that occurs after transplantation when a patient’s T-cell immune response is compromised by …